Sensitivity of clinical isolates of Candida species to antifungal drugs

JK Science

Volumn 8, Issue 4, 2006, Pages 214-216

  Berry, Vandana ^a   Badyal, Dinesh K ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Antifungal drugs; Candida; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; NYSTATIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CONTROLLED STUDY; DRUG USE; FUNGUS ISOLATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MYCOSIS; NONHUMAN; PREVALENCE;

EID: 33846943038     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hajjeh RAAN, Sofair LH, Harrison GM. Ho SW, Luh KT. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
2. Pappas PG, Rex JH, Sobel JD. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
3. Chen KY, Ko SC, Hsueh PR, Luh KT, Yang PC. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 2001; 120: 177-84.
4. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy ofcandidiasis. Diagn Microbiol Infect Dis 2004; 48: 153-60.
5. Abuhammour W, Habte-Gaber E. Newer antifungal agents. Ind J Pediatr 2004; 71: 253-59.
6. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004; 25: 60-64.
7. Po-Ren H, Yeu-Jun L, Yin-Ching C et al. Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003. Antimicrobial Agents and Chemotherapy 2005; 49: 512-17.
8. Ellabib MS, ElJariny IA. In vitro activity of 6 antifungal agents on Candida species isolated as causative agents from vaginal and other clinical specimens. Saudi Med J 2001; 22: 860-63.
9. Kuriyama T, Williams DW, Bagg J et al. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol. 2005; 20: 349-53.
10. Yang YL, Li SY, Cheng HH, Lo HJ. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Microbiol infect Dis 2005; 51: 179-83.
11. Marco F, Pfaller MA, Messer S, Jones RN. In vitroactivities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998; 42: 161-63.